Terms of use

Privacy

Privacy Settings

Imprint

Contact Us

Carolina Teichmann Cravo

Get in touch and send us an email.

Want to know more?

Linkedin

Facebook

About Us

Why Redcare?

Facts & Figures

Public Affairs

Our Company

About Redcare

News & Events

Sign up

Newsroom

Our Impact

Offset

Sustainability

Overview

Share

News

Events and Publications

Corporate Governance

Contact

Investor Relations

Our Culture

Teams

Jobs

FAQs

Career

No results found

About us

Careers

LinkedIn

Twitter

SHOP APOTHEKE EUROPE N.V.: Consolidated revenues grow by +53% to over EUR 191 m in the first nine months of 2017.

NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.

SHOP APOTHEKE EUROPE: Consolidated revenues grow by +53% to over EUR 191 m in the first nine months of 2017.

 SHOP APOTHEKE EUROPE N. V. again achieved strong growth in the first nine months of the financial year 2017 (01.01. - 30.09.). According to preliminary calculations, the Group increased revenues by +53% to more than EUR 191 m after EUR 125 m in the corresponding period of the previous year. Thus, SHOP APOTHEKE EUROPE is once again the fastest growing online pharmacy in Europe.

In the core market shown in the "Germany" segment, which generates the highest sales, SHOP APOTHEKE EUROPE increased its revenue by +31% to almost EUR 138 m (previous year: EUR 105 m) in the reporting period. In the "International" segment, which includes the European markets of France, Italy, Spain, Austria, Belgium and the Netherlands, the company nearly tripled its revenue to around EUR 53 m (9M/2016: EUR 18 m) during the reporting period. The "Germany Services" segment, which comprises webshop services, generated sales of EUR 0.6 m (9M/2016: EUR 1.2 m) after eliminations for intragroup services.

Against the background of the planned acquisition of Europa Apotheek, which is expected to be completed in November 2017, the Management Board anticipates a further acceleration of growth at Group level in the fourth quarter of 2017, with a forecast for the Group's sales growth - as already reported on 25 September 2017 - of between +55% and +65%, after +45% to +55% earlier. The forecast for the consolidated EBITDA margin before non-recurring transaction expenses remains unchanged at -2.0% to -3.0%.

SHOP APOTHEKE EUROPE will publish its final figures and the complete interim report on 13 November 2017.

SHOP APOTHEKE EUROPE is Continental Europe's leading online OTC pharmacy with a portfolio that focuses on OTC medication and pharmacy-related beauty and care products (BPC). With the takeover of Europa Apotheek planned for November 2017, SHOP APOTHEKE EUROPE will significantly enhance its European market leadership with an expanded product range for the whole family. The combination will create the fastest growing integrated online pharmacy with pro forma sales of around EUR 318 m in 2016.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and The Netherlands. In Germany, the TÜV-certified 

 is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to nearly 2.4 m active customers (as of September 2017) quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated sales of about EUR 191 m in the first nine months of 2017 and a growth of +53% compared to the same period last year. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices in Cologne, Düsseldorf and Tongeren, Belgium. The online pharmacy has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016. 